Calton & Associates’s Axcelis ACLS Stock Holding History

Calton & Associates’s Portfolio ACLS Stock Details ACLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-6,238	Closed	-$471K	–	240
2022 Q1	$471K	Buy	+6,238	New	+$426K	0.14%	174

Other funds holding ACLS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Senvest Management New York $3.41B AUM 66.27% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Calton & Associates's ACLS Position: Q2 2022 in Review

Calton & Associates sold out of Axcelis (ACLS) in Q2 2022, closing a stake of 6,238 shares — an estimated $471K sold.

Calton & Associates first reported a position in ACLS in Q1 2022 and held it in 1 quarter. The position peaked at $471K in Q1 2022. 276 funds tracked by Wall St. Rank hold ACLS as of Q2 2022.

Calton & Associates reported no remaining Axcelis position as of Q2 2022 after selling out during the quarter.
Calton & Associates sold 6,238 Axcelis shares in Q2 2022, an estimated $471K.
Calton & Associates first reported a position in Axcelis in Q1 2022 and held it in 1 quarter.
Calton & Associates's Axcelis position peaked at $471K in Q1 2022.
276 funds tracked by Wall St. Rank held Axcelis as of Q2 2022.

Based on Calton & Associates's 13F filing for Q2 2022, filed 12 Jul 2022.